$60.43
3.59% today
Nasdaq, Sep 11, 09:17 pm CET
ISIN
US69366J2006
Symbol
PTCT

PTC Therapeutics, Inc. Stock price

$58.33
+15.03 34.71% 1M
+5.84 11.13% 6M
+13.19 29.22% YTD
+26.79 84.94% 1Y
+5.26 9.91% 3Y
+12.06 26.06% 5Y
+20.41 53.82% 10Y
+41.84 253.73% 20Y
Nasdaq, Closing price Wed, Sep 10 2025
-0.09 0.15%
ISIN
US69366J2006
Symbol
PTCT
Industry

Key metrics

Basic
Market capitalization
$4.6b
Enterprise Value
$5.0b
Net debt
$412.1m
Cash
$2.0b
Shares outstanding
79.4m
Valuation (TTM | estimate)
P/E
7.2 | 7.6
P/S
2.6 | 2.6
EV/Sales
2.9 | 2.8
EV/FCF
7.2
P/B
negative
Financial Health
Equity Ratio
-64.4%
Return on Equity
33.1%
ROCE
43.7%
ROIC
216.0%
Debt/Equity
-11.6
Financials (TTM | estimate)
Revenue
$1.8b | $1.8b
EBITDA
$891.3m | $857.1m
EBIT
$877.1m | $867.9m
Net Income
$629.2m | $608.5m
Free Cash Flow
$697.4m
Growth (TTM | estimate)
Revenue
96.0% | 119.9%
EBITDA
14,663.4% | 1,151.3%
EBIT
546.8% | 710.0%
Net Income
231.2% | 267.5%
Free Cash Flow
638.0%
Margin (TTM | estimate)
Gross
97.1%
EBITDA
50.5% | 48.3%
EBIT
49.7%
Net
35.7% | 34.3%
Free Cash Flow
39.5%
More
EPS
$8.1
FCF per Share
$8.8
Short interest
9.4%
Employees
939
Rev per Employee
$860.0k
Show more

Is PTC Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

PTC Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a PTC Therapeutics, Inc. forecast:

16x Buy
70%
6x Hold
26%
1x Sell
4%

Analyst Opinions

23 Analysts have issued a PTC Therapeutics, Inc. forecast:

Buy
70%
Hold
26%
Sell
4%

Financial data from PTC Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,765 1,765
96% 96%
100%
- Direct Costs 51 51
25% 25%
3%
1,714 1,714
106% 106%
97%
- Selling and Administrative Expenses 324 324
8% 8%
18%
- Research and Development Expense 508 508
5% 5%
29%
891 891
14,663% 14,663%
50%
- Depreciation and Amortization 14 14
93% 93%
1%
EBIT (Operating Income) EBIT 877 877
547% 547%
50%
Net Profit 629 629
231% 231%
36%

In millions USD.

Don't miss a Thing! We will send you all news about PTC Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PTC Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
3 days ago
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 9:15 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst All right. Welcome, everyone, to this session of the Morgan...
Neutral
Seeking Alpha
4 days ago
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Cantor Global Healthcare Conference 2025 September 3, 2025 8:35 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Presentation Kristen Kluska Analyst Hi, good morning, everybody. I'm Kristen Kluska, one of the biotech an...
Neutral
Seeking Alpha
4 days ago
PTC Therapeutics, Inc. (NASDAQ:PTCT ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 11:00 AM EDT Company Participants Matthew Klein - CEO & Director Pierre Gravier - Chief Financial Officer Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Presentation Tiago Fauth Equity Analyst All right. Thanks, everyone, for joining us.
More PTC Therapeutics, Inc. News

Company Profile

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically-differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Head office United States
CEO Matthew Klein
Employees 939
Founded 1998
Website www.ptcbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today